Contributing Editors
-
Outsourcing Manufacturing Doesn't Outsource Diversion Risk
11/19/2026
A sponsor should approach diversion risk by embedding controls into the three phases of the CDMO relationship: selection, the agreement, and ongoing management.
-
Understanding FDA's 2026 Guidance For Generic Transdermal And Topical Delivery System Adhesion Assessments
11/17/2026
Patch adhesion is more than a stickiness test. Let's take a closer look at the FDA's July 2026 final guidance, Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs.
-
You Can't CAPA What You Can't Locate
11/16/2026
Don’t reinvent the wheel — adapt it. Locate before you correct, because where a failure appears isn’t necessarily where it gets fixed.
-
Why CMC Must Shape Critical Decisions Early In Development
11/11/2026
Case studies reveal the gap between research progress and clinical readiness. In these stories, earlier CMC involvement might have saved resources and staved off delays.
-
Developing Your Vapor Phase Hydrogen Peroxide Cycle
11/10/2026
Vapor phase hydrogen peroxide has been used for decades as a surface decontaminant in pharma/biotech, but there has been little guidance on how to establish the parameters. Here's an industry consensus from BioPhorum.
-
IT/OT Convergence Could Lighten Biopharma's Automation Burden
11/9/2026
Integration lets frameworks talk to each other through middleware. Convergence brings them under the same architecture, which can can reduce costs and maintenance.
-
How Peptides Are Expanding The Possibilities Of Drug Discovery
11/9/2026
GLP-1 therapies demonstrate the impact peptide medicines have. The opportunity ahead is to extend that impact across a much broader range of biology and achieve new ways to intervene.
-
The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
11/9/2026
A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.
-
Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
11/6/2026
Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.
-
What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
11/4/2026
The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.